Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (EYPT) reported financial results for Q4 and the full year ended December 31, 2020. Total net revenue increased to $34.4 million, up from $20.4 million in 2019. Net product revenue for the year was $20.8 million, compared to $16.8 million in the prior year. However, the company incurred a net loss of $45.4 million, or $3.54 per share. EyePoint raised $115.1 million through a public stock offering in February 2021, strengthening their financial position. They also highlighted progress in their EYP-1901 clinical trial for wet AMD.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to present at two upcoming virtual conferences in March 2021. The first event is the Cowen Healthcare Conference on March 3, from 2:40-3:10 PM Eastern Time, featuring a fireside chat. The second event is the H.C. Wainwright Global Life Sciences Conference on March 9, at 7:00 AM Eastern Time, with a formal presentation. Investors can access a live webcast and archived replay on the company’s website for 90 days post-event. EyePoint focuses on therapeutics for serious eye disorders, leveraging Durasert® technology and offering products like YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will hold a conference call on March 4, 2021, at 8:30 a.m. ET to discuss its full year 2020 financial results and recent business highlights. The call can be accessed by dialing (877)-312-7507 or (631)-813-4828 with conference ID 1261618. The company focuses on developing therapeutics for serious eye disorders, leveraging Durasert® technology for sustained drug delivery. EyePoint has two commercial products: YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has completed a public offering of 10,465,000 shares at $11.00 per share, raising approximately $115.1 million, post-underwriting expenses. The offering included an option for underwriters to purchase an additional 1,365,000 shares. The net proceeds will support the advancement of EYP-1901 for treating wet AMD, pipeline, commercial programs, and general corporate purposes. This was conducted under a previously filed shelf registration statement with the SEC.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its intention to conduct an underwritten public offering of common stock. The offering is dependent on market conditions, with no certainty regarding its completion or specific terms. EyePoint plans to utilize the net proceeds for advancing EYP-1901, pipeline initiatives, and general corporate purposes. Underwriters Cowen and Guggenheim Securities will lead the offering, which is registered under Form S-3 with the SEC. A preliminary prospectus will provide additional details as it becomes available.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated a Phase 1 clinical trial for EYP-1901, an innovative twice-yearly sustained delivery treatment targeting wet age-related macular degeneration (wet AMD). The trial will involve thirteen patients previously responsive to anti-VEGF treatments, focusing on safety and visual acuity outcomes. EYP-1901 utilizes the proprietary Durasert® technology combined with vorolanib, which previously showed efficacy in Phase 2 trials. This advancement could enhance treatment convenience and market potential, particularly for millions affected by wet AMD.
EyePoint Pharmaceuticals (EYPT) provided a business update for Q4 and full-year 2020, showing estimated net product revenues ranging from $6.2M to $6.6M, down from $7.9M in 2019. EYP-1901, a potential anti-VEGF treatment for wet AMD, had an IND filed in December 2020, with a Phase 1 trial expected in Q1 2021. Customer demand for DEXYCU and YUTIQ rose by 30% and 10%, respectively. Cash and cash equivalents were approximately $44M as of December 31, 2020. A partnership with Ocumension Therapeutics brought a $15.7M injection, and a royalty agreement with SWK Holdings added $16.5M.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a $15.7 million equity investment from Ocumension Therapeutics, a Chinese ophthalmic company. Ocumension acquired approximately 3.01 million shares at a price of $5.22 per share as of December 29, 2020. The investment marks a significant partnership for the commercialization of EyePoint's products, YUTIQ and DEXYCU, in Asia. The company estimates cash and cash equivalents at around $44 million as of December 31, 2020, which will support operations into the latter part of 2021, assuming no major disruptions due to COVID-19.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a royalty monetization agreement with SWK Holdings for royalties related to its ILUVIEN® product. The deal provides EyePoint with a one-time payment of $16.5 million, of which $15 million will reduce long-term debt and $1.5 million will support product development. This transaction is expected to lower annual interest payments by approximately $1.7 million, enhancing EyePoint's financial stability as it advances its ocular disease pipeline, including EYP-1901 for wet age-related macular degeneration.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a 1-for-10 reverse stock split effective at 5:00 p.m. ET on December 8, 2020. Starting December 9, 2020, the stock will trade under a new CUSIP number. The move aims to regain compliance with Nasdaq's $1.00 minimum closing bid price requirement. The split reduces the number of outstanding shares from approximately 151.3 million to about 15.13 million, affecting all stockholders uniformly. The company's authorized shares and par values remain unchanged. Computershare is appointed as the exchange agent for this process.